Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Total Valuation
Krystal Biotech has a market cap or net worth of $3.80B. The enterprise value is ―.
Market Cap$3.80B
Enterprise Value―
Share Statistics
Krystal Biotech has 28,898,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,898,680
Owned by Insiders22.42%
Owned by Institutions0.06%
Financial Efficiency
Krystal Biotech’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 6.43%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)6.43%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.06M
Profits Per Employee324.21K
Employee Count275
Asset Turnover0.28
Inventory Turnover0.76
Valuation Ratios
The current PE Ratio of Krystal Biotech is 50.24. Krystal Biotech’s PEG ratio is 0.85.
PE Ratio50.24
PS Ratio0.00
PB Ratio5.59
Price to Fair Value4.73
Price to FCF44.45
Price to Operating Cash Flow42.85
PEG Ratio0.85
Income Statement
In the last 12 months, Krystal Biotech had revenue of 290.51M and earned 89.16M in profits. Earnings per share was 3.12.
Revenue290.51M
Gross Profit270.45M
Operating Income65.69M
Pretax Income95.36M
Net Income89.16M
EBITDA109.91M
Earnings Per Share (EPS)3.12
Cash Flow
In the last 12 months, operating cash flow was 123.42M and capital expenditures -4.24M, giving a free cash flow of 119.18M billion.
Operating Cash Flow123.42M
Free Cash Flow119.18M
Free Cash Flow per Share4.12
Dividends & Yields
Krystal Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-22.58%
50-Day Moving Average164.63
200-Day Moving Average173.19
Relative Strength Index (RSI)27.96
Average Volume (3m)374.65K
Important Dates
Krystal Biotech upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Krystal Biotech as a current ratio of 7.28, with Debt / Equity ratio of 0.77%
Current Ratio7.28
Quick Ratio7.02
Debt to Market Cap0.00
Net Debt to EBITDA-3.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Krystal Biotech has paid 6.20M in taxes.
Income Tax6.20M
Effective Tax Rate0.06
Enterprise Valuation
Krystal Biotech EV to EBITDA ratio is 37.68, with an EV/FCF ratio of 34.75.
EV to Sales14.26
EV to EBITDA37.68
EV to Free Cash Flow34.75
EV to Operating Cash Flow33.56
Balance Sheet
Krystal Biotech has $597.52M in cash and marketable securities with $7.26M in debt, giving a net cash position of -$590.26M billion.
Cash & Marketable Securities$597.52M
Total Debt$7.26M
Net Cash-$590.26M
Net Cash Per Share-$20.43
Tangible Book Value Per Share$33.10
Margins
Gross margin is 92.41%, with operating margin of 22.61%, and net profit margin of 30.69%.
Gross Margin92.41%
Operating Margin22.61%
Pretax Margin32.82%
Net Profit Margin30.69%
EBITDA Margin37.83%
EBIT Margin35.52%
Analyst Forecast
The average price target for Krystal Biotech is $203.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$203.43
Price Target Upside60.59% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast247.53%
EPS Growth Forecast118.34%